|29.71||+0.1500||+0.51%||Vol 2.21M||1Y Perf 20.55%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||30.40||Analyst Rating||Moderate Buy 2.44|
|Potential %||2.32||Finscreener Ranking||★★ 44.59|
|Insiders Trans % 3/6/12 mo.||-100/-88/-71||Value Ranking||★+ 42.90|
|Insiders Value % 3/6/12 mo.||-100/-100/-96||Growth Ranking||★+ 43.11|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-96||Income Ranking||— -|
|Price Range Ratio 52W %||72.02||Earnings Rating||Strong Buy|
|Market Cap||4.88B||Earnings Date||27th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Jul 2022|
|Estimated EPS Next Report||-0.12|
|EPS Growth Next 5 Years %||25.10|
|Avg. Weekly Volume||1.85M|
|Avg. Monthly Volume||1.40M|
|Avg. Quarterly Volume||1.57M|
Alkermes plc (NASDAQ: ALKS) stock closed at 29.71 per share at the end of the most recent trading day (a 0.51% change compared to the prior day closing price) with a volume of 2.21M shares and market capitalization of 4.88B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2245 people. Alkermes plc CEO is Richard F. Pops.
The one-year performance of Alkermes plc stock is 20.55%, while year-to-date (YTD) performance is 27.73%. ALKS stock has a five-year performance of -49.19%. Its 52-week range is between 21.24 and 33, which gives ALKS stock a 52-week price range ratio of 72.02%
Alkermes plc currently has a PE ratio of -73.80, a price-to-book (PB) ratio of 4.28, a price-to-sale (PS) ratio of 3.83, a price to cashflow ratio of 26.90, a PEG ratio of 2.32, a ROA of -3.20%, a ROC of -3.68% and a ROE of -5.80%. The company’s profit margin is -5.13%, its EBITDA margin is 1.80%, and its revenue ttm is $1.20 Billion , which makes it $7.32 revenue per share.
Of the last four earnings reports from Alkermes plc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Alkermes plc’s next earnings report date is 27th Jul 2022.
The consensus rating of Wall Street analysts for Alkermes plc is Moderate Buy (2.44), with a target price of $30.4, which is +2.32% compared to the current price. The earnings rating for Alkermes plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alkermes plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alkermes plc has a Buy technical analysis rating based on Technical Indicators (ADX : 8.90, ATR14 : 1.22, CCI20 : 88.36, Chaikin Money Flow : 0.07, MACD : 0.00, Money Flow Index : 53.79, ROC : 2.63, RSI : 58.14, STOCH (14,3) : 86.21, STOCH RSI : 1.00, UO : 52.64, Williams %R : -13.79), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alkermes plc in the last 12-months were: Blair C. Jackson (Option Excercise at a value of $827 483), Blair C. Jackson (Sold 49 999 shares of value $1 480 335 ), Brian P. Mckeon (Buy at a value of $264 269), Brian P. Mckeon (Option Excercise at a value of $0), Christian Todd Nichols (Option Excercise at a value of $0), Christian Todd Nichols (Sold 7 474 shares of value $211 203 ), Craig C. Hopkinson (Option Excercise at a value of $0), Craig C. Hopkinson (Sold 14 289 shares of value $354 692 ), David A. Daglio (Option Excercise at a value of $0), David Joseph Gaffin (Option Excercise at a value of $231 700), David Joseph Gaffin (Sold 14 000 shares of value $364 000 ), David W. Anstice (Option Excercise at a value of $292 000), David W. Anstice (Sold 20 000 shares of value $491 504 ), Emily Peterson Alva (Buy at a value of $49 861), Emily Peterson Alva (Option Excercise at a value of $0), Frank Anders Wilson (Option Excercise at a value of $0), Iain M. Brown (Option Excercise at a value of $662 000), Iain M. Brown (Sold 40 000 shares of value $1 199 600 ), Michael J. Landine (Option Excercise at a value of $1 655 000), Michael J. Landine (Sold 100 000 shares of value $2 853 270 ), Nancy J. Wysenski (Option Excercise at a value of $0), Nancy L. Snyderman (Buy at a value of $10 005), Nancy L. Snyderman (Option Excercise at a value of $0), Richard B. Gaynor (Option Excercise at a value of $0), Richard F. Pops (Option Excercise at a value of $7 447 499), Richard F. Pops (Sold 347 257 shares of value $9 717 783 ), Shane M. Cooke (Option Excercise at a value of $827 500), Shane M. Cooke (Sold 50 000 shares of value $1 434 375 ), Wendy L. Dixon (Option Excercise at a value of $0)
Thu, 28 Apr 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Achieve Life Sciences (ACHV)- TipRanks. All rights reserved.
Wed, 27 Apr 2022 12:06 GMT Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and BioSig Technologies (BSGM)- TipRanks. All rights reserved.
Thu, 21 Apr 2022 22:16 GMT Alkermes (ALKS) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Thu, 17 Feb 2022 09:20 GMT Alkermes (ALKS) Gets a Buy Rating from Mizuho Securities- TipRanks. All rights reserved.
Tue, 15 Feb 2022 13:46 GMT Alkermes (ALKS) Received its Third Buy in a Row- TipRanks. All rights reserved.
Wed, 09 Feb 2022 12:40 GMT Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), ProQR (PRQR) and Ovid Therapeutics (OVID)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.